Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Fig. 1

M-protein levels over time. After initial presentation in 2010, the patient received five rounds of treatment and relapsed each time. The patient received the first dose of daratumumab (16 mg/kg) in October 2013 when he enrolled in the SIRIUS study. M-protein levels were measured at the local laboratory and then centrally after the first dose of daratumumab

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us